 Tumor Escape
"Tumor Escape" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The ability of tumors to evade destruction by the IMMUNE SYSTEM. Theories concerning possible mechanisms by which this takes place involve both cellular immunity (IMMUNITY, CELLULAR) and humoral immunity (ANTIBODY FORMATION), and also costimulatory pathways related to CD28 antigens (ANTIGENS, CD28) and CD80 antigens (ANTIGENS, CD80).
| Descriptor ID |
D019139
|
| MeSH Number(s) |
G12.425.905
|
| Concept/Terms |
Tumor Escape- Tumor Escape
- Immune Evasion, Tumor
- Tumor Immune Evasion
- Evasion, Tumor Immune
- Evasions, Tumor Immune
- Immune Evasions, Tumor
- Tumor Immune Evasions
- Immune Escape, Tumor
- Tumor Immune Escape
|
Below are MeSH descriptors whose meaning is more general than "Tumor Escape".
Below are MeSH descriptors whose meaning is more specific than "Tumor Escape".
This graph shows the total number of publications written about "Tumor Escape" by people in this website by year, and whether "Tumor Escape" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 | | 2001 | 1 | 0 | 1 | | 2002 | 0 | 1 | 1 | | 2003 | 1 | 0 | 1 | | 2004 | 1 | 1 | 2 | | 2005 | 1 | 0 | 1 | | 2006 | 1 | 1 | 2 | | 2007 | 0 | 1 | 1 | | 2009 | 1 | 1 | 2 | | 2010 | 3 | 0 | 3 | | 2011 | 1 | 1 | 2 | | 2012 | 0 | 1 | 1 | | 2013 | 1 | 0 | 1 | | 2014 | 0 | 1 | 1 | | 2015 | 0 | 1 | 1 | | 2016 | 0 | 3 | 3 | | 2017 | 2 | 2 | 4 | | 2018 | 1 | 1 | 2 | | 2019 | 0 | 1 | 1 | | 2020 | 1 | 1 | 2 | | 2021 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Tumor Escape" by people in Profiles.
-
Gkountidi AO, Garnier L, Dubrot J, Angelillo J, Harlé G, Brighouse D, Wrobel LJ, Pick R, Scheiermann C, Swartz MA, Hugues S. MHC Class II Antigen Presentation by Lymphatic Endothelial Cells in Tumors Promotes Intratumoral Regulatory T cell-Suppressive Functions. Cancer Immunol Res. 2021 07; 9(7):748-764.
-
Han YJ, Zhang J, Lee JH, Mason JM, Karginova O, Yoshimatsu TF, Hao Q, Hurley I, Brunet LP, Prat A, Prasanth KV, Gack MU, Olopade OI. The BRCA1 Pseudogene Negatively Regulates Antitumor Responses through Inhibition of Innate Immune Defense Mechanisms. Cancer Res. 2021 03 15; 81(6):1540-1551.
-
Liu S, Galat V, Galat Y, Lee YKA, Wainwright D, Wu J. NK cell-based cancer immunotherapy: from basic biology to clinical development. J Hematol Oncol. 2021 01 06; 14(1):7.
-
Jou J, Harrington KJ, Zocca MB, Ehrnrooth E, Cohen EEW. The Changing Landscape of Therapeutic Cancer Vaccines-Novel Platforms and Neoantigen Identification. Clin Cancer Res. 2021 02 01; 27(3):689-703.
-
Bao R, Stapor D, Luke JJ. Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types. Genome Med. 2020 10 27; 12(1):90.
-
Kline J, Godfrey J, Ansell SM. The immune landscape and response to immune checkpoint blockade therapy in lymphoma. Blood. 2020 02 20; 135(8):523-533.
-
Guram K, Kim SS, Wu V, Sanders PD, Patel S, Schoenberger SP, Cohen EEW, Chen SY, Sharabi AB. A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy. Front Immunol. 2019; 10:491.
-
Olson DJ, Luke JJ. The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development. Immunotherapy. 2019 02; 11(3):155-159.
-
Chao JL, Savage PA. Unlocking the Complexities of Tumor-Associated Regulatory T Cells. J Immunol. 2018 01 15; 200(2):415-421.
-
Spranger S, Gajewski TF. Impact of oncogenic pathways on evasion of antitumour immune responses. Nat Rev Cancer. 2018 03; 18(3):139-147.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|